FDA Clearance Tracker · K201269
Accula Strep A Test
Last checked: Nov 19, 2026Latest source record: Nov 9, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Nov 9, 2020
Substantially Equivalent
Time to decision
181 days
Received May 12, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K201269
- Device name
- Accula Strep A Test
- Applicant
- Mesa Biotech, Inc.
- Applicant location
- San Diego, CA
- Received
- May 12, 2020
- Decided
- Nov 9, 2020
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.2680
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PGX. The earliest in FDA's data is DEN140005, decided Apr 16, 2014.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K201269
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Mesa Biotech, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Accula RSV Test510(k)
K181443 · Decided Nov 23, 2018 · 176 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
- Accula Flu A/Flu B Test510(k)
K171641 · Decided Feb 6, 2018 · 249 days after receipt
Device type: Influenza A And Influenza B Multiplex Nucleic Acid Assay (OZE) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.